TNF Inhibition As Novel Therapy For Refractory Sarcoidosis: Long Term Follow Up
Nadera Sweiss(University of Illinois Chicago), Michael H. Ellman(University of Chicago), James F. Curran(University of Chicago), Linda Hushaw(University of Chicago), Robert P. Baughman(University of Cincinnati), Timothy B. Niewold(Hospital for Special Surgery)
Cited by 2
Related Papers
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
|Critical Care Medicine|1997|863
ERS clinical practice guidelines on treatment of sarcoidosis
|European Respiratory Journal|2021|579
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
|PubMed|2014|505
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
PD-1 up-regulation on CD4 <sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
|Science Translational Medicine|2018|364